Drug Profile
Research programme: inositol phosphoglycans - SR Pharma
Alternative Names: IPGs programme - SR PharmaLatest Information Update: 16 May 2007
Price :
$50
*
At a glance
- Originator SR Pharma
- Developer Silence Therapeutics
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Cancer
Most Recent Events
- 10 Dec 2003 Preclinical trials in Cancer in United Kingdom (unspecified route)